Date: 2013-08-06
Type of information: Grant
Company: Pluristem Therapeutics (Israel)
Investors: Office of the Chief Scientist (OCS -Israel)
Amount: $3.3 Million (€2.49 million)
Funding type: grant
Planned used: The grant will be used to cover R&D expenses for the period January 2013 to December 2013.
Others: * On August 6, 2013, Pluristem Therapeutics has announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a 12 million New Israeli Shekels (approximately $3.3 million) grant from the Office of the Chief Scientist (OCS) within the Israeli Ministry of Economy.
According to the OCS grant terms, Pluristem Ltd. is required to pay royalties in the rate of 3% - 5% on sales of products and services derived from technology developed using this and other OCS grants until 100% of the dollar-linked grants amount plus interest are repaid. In the absence of such sales, no payment is required.
Therapeutic area: Cardiovascular diseases - Regenerative medicine
